company background image
IOBT logo

IO Biotech NasdaqGS:IOBT Stock Report

Last Price

US$1.14

Market Cap

US$79.7m

7D

10.7%

1Y

-11.6%

Updated

27 May, 2025

Data

Company Financials +

IOBT Stock Overview

A clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. More details

IOBT fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

IO Biotech, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for IO Biotech
Historical stock prices
Current Share PriceUS$1.14
52 Week HighUS$1.73
52 Week LowUS$0.66
Beta0
1 Month Change18.75%
3 Month Change14.00%
1 Year Change-11.63%
3 Year Change-76.40%
5 Year Changen/a
Change since IPO-92.72%

Recent News & Updates

Can IO Biotech (NASDAQ:IOBT) Afford To Invest In Growth?

Apr 02
Can IO Biotech (NASDAQ:IOBT) Afford To Invest In Growth?

Recent updates

Can IO Biotech (NASDAQ:IOBT) Afford To Invest In Growth?

Apr 02
Can IO Biotech (NASDAQ:IOBT) Afford To Invest In Growth?

Here's Why We're A Bit Worried About IO Biotech's (NASDAQ:IOBT) Cash Burn Situation

Dec 17
Here's Why We're A Bit Worried About IO Biotech's (NASDAQ:IOBT) Cash Burn Situation

We're A Little Worried About IO Biotech's (NASDAQ:IOBT) Cash Burn Rate

Jun 12
We're A Little Worried About IO Biotech's (NASDAQ:IOBT) Cash Burn Rate

We Think IO Biotech (NASDAQ:IOBT) Needs To Drive Business Growth Carefully

Feb 10
We Think IO Biotech (NASDAQ:IOBT) Needs To Drive Business Growth Carefully

We Think IO Biotech (NASDAQ:IOBT) Needs To Drive Business Growth Carefully

Jun 15
We Think IO Biotech (NASDAQ:IOBT) Needs To Drive Business Growth Carefully

We Think IO Biotech (NASDAQ:IOBT) Needs To Drive Business Growth Carefully

Jan 20
We Think IO Biotech (NASDAQ:IOBT) Needs To Drive Business Growth Carefully

IO Biotech names new CFO

Oct 13

We're Keeping An Eye On IO Biotech's (NASDAQ:IOBT) Cash Burn Rate

Sep 27
We're Keeping An Eye On IO Biotech's (NASDAQ:IOBT) Cash Burn Rate

IO Biotech GAAP EPS of -$0.64

Aug 11

We're Keeping An Eye On IO Biotech's (NASDAQ:IOBT) Cash Burn Rate

Jun 14
We're Keeping An Eye On IO Biotech's (NASDAQ:IOBT) Cash Burn Rate

We Think IO Biotech (NASDAQ:IOBT) Needs To Drive Business Growth Carefully

Feb 25
We Think IO Biotech (NASDAQ:IOBT) Needs To Drive Business Growth Carefully

Shareholder Returns

IOBTUS BiotechsUS Market
7D10.7%-1.0%-0.3%
1Y-11.6%-10.4%11.3%

Return vs Industry: IOBT exceeded the US Biotechs industry which returned -12.9% over the past year.

Return vs Market: IOBT underperformed the US Market which returned 9.1% over the past year.

Price Volatility

Is IOBT's price volatile compared to industry and market?
IOBT volatility
IOBT Average Weekly Movement11.3%
Biotechs Industry Average Movement12.2%
Market Average Movement8.0%
10% most volatile stocks in US Market17.2%
10% least volatile stocks in US Market4.2%

Stable Share Price: IOBT has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: IOBT's weekly volatility (11%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
201480MBZ Zoccawww.iobiotech.com

IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company’s lead therapeutic cancer vaccine candidate includes IO102-IO103, which targets cancer cells and immune-suppressive cells in the tumor microenvironment that express indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide to target T cells that recognize epitopes derived from Arginase 1, which is an immunoregulatory enzyme highly expressed in difficult-to-treat tumors associated with high levels of myeloid-derived suppressor cells, including renal cell carcinoma, head and neck, breast, pancreatic, ovarian, colorectal, and prostate cancers.

IO Biotech, Inc. Fundamentals Summary

How do IO Biotech's earnings and revenue compare to its market cap?
IOBT fundamental statistics
Market capUS$79.72m
Earnings (TTM)-US$98.45m
Revenue (TTM)n/a
0.0x
P/S Ratio
-0.8x
P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
IOBT income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$98.46m
Earnings-US$98.45m

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)-1.49
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did IOBT perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/27 18:06
End of Day Share Price 2025/05/27 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

IO Biotech, Inc. is covered by 8 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Emily BodnarH.C. Wainwright & Co.
Christopher HowertonJefferies LLC
Roger SongJefferies LLC